SCHEMBL26075889

SCHEMBL26075889

COCc1ccc(-c2ccc(-c3cc(C)c4cc(P)ccc4n3)cc2F)cc1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 9/20 0.38
▸ ESR2 Q92731 9/20 0.38
▸ DHODH Q02127 4/20 0.36
▸ S1PR1 P21453 1/20 0.34
▸ S1PR3 Q99500 1/20 0.34
▸ DGAT1 O75907 1/20 0.33
▸ SOAT1 P35610 1/20 0.33
▸ ACACA Q13085 2/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ MEN1 O00255 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ LMNA P02545 1/20 0.32
▸ GAA P10253 1/20 0.32
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ KMT2A Q03164 1/20 0.32
▸ SMN1; SMN2 Q16637 1/20 0.32
▸ CHEK1 O14757 1/20 0.32
▸ TOP1 P11387 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26075890 0.90 ESR1 (0.38) ESR1ESR2DHODHS1PR1S1PR3
SCHEMBL26075302 0.89 DHODH (0.42) ESR1ESR2DHODHMEN1KMT2A
SCHEMBL26075865 0.86 ACACA (0.46) ACACAKDM4EMEN1ALDH1A1LMNA
SCHEMBL26075399 0.85 FEN1 (0.39) ESR1ESR2DHODHTOP1
SCHEMBL26075897 0.85 SQOR (0.37) ESR1ESR2DHODHACACAALDH1A1
SCHEMBL26075892 0.85 S1PR1 (0.41) ESR1ESR2DHODHS1PR1S1PR3
SCHEMBL26075885 0.83 HMOX1 (0.41) ESR1ESR2ACACAKDM4EMEN1
SCHEMBL26075891 0.82 DHODH (0.44) ESR1ESR2DHODHACACAKDM4E
SCHEMBL26075894 0.81 ESR1 (0.37) ESR1ESR2KDM4EALDH1A1LMNA
SCHEMBL26075893 0.81 ESR1 (0.37) ESR1ESR2TOP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT OHIO STATE INNOVATION FOUNDATION (US) 2023-09-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303710-A1 METHODS AND COMPOSITIONS FOR INHIBITION OF DIHYDROOROTATE DEHYDROGENASE IN COMBINATION WITH AN ANTI-CD38 THERAPEUTIC AGENT DHODH, CD38, DPYD ESR1 4427/4885ESR2 4530/4885DHODH 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback